Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
EMA guidance · 2026-07-16EMA Opinion: Xervyteg (allogeneic faecal microbiota, pooled) — MaaT PHARMA
EMA opinion on Xervyteg (allogeneic faecal microbiota, pooled) for graft-versus-host disease.
-
EMA guidance · 2026-07-15EMA Opinion under re-examination: Yartemlea (narsoplimab) — Omeros Ireland Limited
EMA opinion under re-examination for Yartemlea (narsoplimab) by Omeros Ireland Limited in therapeutic areas including Thrombotic Microangiop…